Literature DB >> 14762750

Clinical outcome of third molars in adults followed during 18 years.

Irja Ventä1, Pekka Ylipaavalniemi, Lauri Turtola.   

Abstract

PURPOSE: The aim of the present study was to follow the clinical changes in third molar status during an 18-year period in patients aged 20 to 38 years. PATIENTS AND METHODS: The series consisted of 118 subjects (37 men and 81 women). In the beginning of the study, the mean age was 20.2 years (SD, +/-0.6 year), and at the end, it was 38.6 years (SD, +/-0.6 year). Panoramic radiographs were taken at baseline and at age 38. All of the subjects were clinically examined at baseline and at the end of the study. A portion of the subjects (n = 69) were also examined at age 32.
RESULTS: Most of the initially unerupted third molars were removed during the follow-up period (73%, maxilla and mandible together). More than half of the initially partially erupted third molars were removed during the follow-up period (64%, maxilla and mandible together). The percentage of erupted third molars found in the mouth at age 38 increased significantly depending on the initial status. Of the initially unerupted, partially erupted, or erupted third molars, 10%, 33%, and 50%, respectively, were erupted at age 38 (maxilla and mandible together). Changes in the status of third molars continued from age 32 to age 38, although to a lesser extent (8%). The 3 third molars with advanced eruption were all maxillary teeth in men.
CONCLUSION: Third molars undergo continuous clinical change on a reduced scale at least up to the age of 38 years.

Entities:  

Mesh:

Year:  2004        PMID: 14762750     DOI: 10.1016/j.joms.2003.04.011

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  8 in total

1.  Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation.

Authors:  Juliet Hounsome; Gerlinde Pilkington; James Mahon; Angela Boland; Sophie Beale; Eleanor Kotas; Tara Renton; Rumona Dickson
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

2.  Surgical removal versus retention for the management of asymptomatic disease-free impacted wisdom teeth.

Authors:  Hossein Ghaeminia; Marloes El Nienhuijs; Verena Toedtling; John Perry; Marcia Tummers; Theo Jm Hoppenreijs; Wil Jm Van der Sanden; Theodorus G Mettes
Journal:  Cochrane Database Syst Rev       Date:  2020-05-04

Review 3.  Impacted wisdom teeth.

Authors:  Thomas B Dodson; Srinivas M Susarla
Journal:  BMJ Clin Evid       Date:  2014-08-29

4.  Pathology related to third molars in the elderly persons.

Authors:  Irja Ventä; Eeva Kylätie; Kaija Hiltunen
Journal:  Clin Oral Investig       Date:  2015-01-17       Impact factor: 3.573

5.  Analysis of the unpredictable migration of impacted mandibular third molars: A pilot study.

Authors:  Cintia-Micaela Chamorro-Petronacci; Mario Pérez-Sayáns; Cosme Gay-Escoda; Berta Rivas-Mundiña; Alejandro-Ismael Lorenzo-Pouso; Pilar Gándara-Vila; Arturo Bilbao-Alonso; Abel García-García
Journal:  J Clin Exp Dent       Date:  2020-12-01

6.  Immunohistochemical analysis of Ki-67 in dental follicle of asymptomatic impacted third molars.

Authors:  Hasan Kucukkolbasi; Alparslan Esen; Ozgur Hilal Erinanc
Journal:  J Oral Maxillofac Pathol       Date:  2014-05

7.  Increased Oral Care Needs and Third Molar Symptoms in Women with Gestational Diabetes Mellitus: A Finnish Gestational Diabetes Case-Control Study.

Authors:  Jenni Pukkila; Sanna Mustaniemi; Shilpa Lingaiah; Olli-Pekka Lappalainen; Eero Kajantie; Anneli Pouta; Risto Kaaja; Johan G Eriksson; Hannele Laivuori; Mika Gissler; Marja Vääräsmäki; Elina Keikkala
Journal:  Int J Environ Res Public Health       Date:  2022-08-28       Impact factor: 4.614

8.  The relation of pericoronal third molar follicle dimension and bcl-2/ki-67 expression: An immunohistochemical study.

Authors:  Seyed Mohammad Razavi; Daryush Hasheminia; Mojde Mehdizade; Bijan Movahedian; Forouz Keshani
Journal:  Dent Res J (Isfahan)       Date:  2012-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.